MXPA06014462A - Composiciones y metodos para tratamiento de enfermedades cardiovasculares. - Google Patents

Composiciones y metodos para tratamiento de enfermedades cardiovasculares.

Info

Publication number
MXPA06014462A
MXPA06014462A MXPA06014462A MXPA06014462A MXPA06014462A MX PA06014462 A MXPA06014462 A MX PA06014462A MX PA06014462 A MXPA06014462 A MX PA06014462A MX PA06014462 A MXPA06014462 A MX PA06014462A MX PA06014462 A MXPA06014462 A MX PA06014462A
Authority
MX
Mexico
Prior art keywords
treatment
methods
compositions
cardiovascular disease
concerned
Prior art date
Application number
MXPA06014462A
Other languages
English (en)
Inventor
Karen Annette Duggan
Original Assignee
Vectus Biosystems Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2004903188A external-priority patent/AU2004903188A0/en
Application filed by Vectus Biosystems Ltd filed Critical Vectus Biosystems Ltd
Publication of MXPA06014462A publication Critical patent/MXPA06014462A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Abstract

La presente invencion se refiere a composiciones y metodos para el tratamiento de algunas condiciones cardiovasculares. En particular, esta se refiere al tratamiento profilactico o terapeutico de fibrosis miocardica o condiciones asociadas administrando composiciones que comprenden peptido vasoactivo intestinal (VIP) y/o fragmento(s) activo(s) del mismo.
MXPA06014462A 2004-06-11 2005-06-10 Composiciones y metodos para tratamiento de enfermedades cardiovasculares. MXPA06014462A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2004903188A AU2004903188A0 (en) 2004-06-11 Treatment of myocardial fibrosis
PCT/AU2005/000835 WO2005120545A1 (en) 2004-06-11 2005-06-10 Compositions and methods for treatment of cardiovascular disease

Publications (1)

Publication Number Publication Date
MXPA06014462A true MXPA06014462A (es) 2007-05-23

Family

ID=35502830

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06014462A MXPA06014462A (es) 2004-06-11 2005-06-10 Composiciones y metodos para tratamiento de enfermedades cardiovasculares.

Country Status (17)

Country Link
US (1) US7951777B2 (es)
EP (1) EP1768689B1 (es)
JP (1) JP4824682B2 (es)
KR (2) KR101638308B1 (es)
CN (1) CN1993137B (es)
AU (1) AU2005251386B8 (es)
BR (1) BRPI0511367B8 (es)
CA (1) CA2573439C (es)
DK (1) DK1768689T3 (es)
ES (1) ES2523659T3 (es)
HK (1) HK1102508A1 (es)
IL (1) IL179931A (es)
MX (1) MXPA06014462A (es)
NZ (1) NZ552130A (es)
RU (1) RU2387454C2 (es)
WO (1) WO2005120545A1 (es)
ZA (1) ZA200700070B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0511367B8 (pt) * 2004-06-11 2021-05-25 Vectus Biosystems Ltd uso de uma composição,composição, uso de vip e/ou de um fragmento ativo do mesmo
CA2574709A1 (en) 2004-07-21 2006-02-02 Tulane University Health Sciences Center Treatment of renal dysfunction and multiple myeloma using pacap compounds
NZ597677A (en) * 2005-12-09 2013-05-31 Vectus Biosystems Ltd Vip fragments and methods of use
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) * 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
JP2009525946A (ja) 2005-12-20 2009-07-16 デューク・ユニヴァーシティ 増強された薬理学的性質を有する活性物質を送達するための方法および組成物
CA2699008A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
EP4074327A1 (en) 2008-06-27 2022-10-19 Duke University Therapeutic agents comprising elastin-like peptides
US20110268789A1 (en) * 2008-09-25 2011-11-03 Min Li Use of pituitary adenylate cyclase-activating polypeptide (pacap) and pacap analogs as adjunctive treatments with anticancer agents
SG10201501316VA (en) * 2008-10-17 2015-05-28 Vectus Biosystems Pty Ltd Compositions and methods for treatment of kidney disorders
US20110288001A1 (en) * 2008-12-18 2011-11-24 Homayoun Sadeghi Biologically active proteins activatable by peptidase
DK2413954T3 (da) 2009-04-02 2014-05-12 Vectus Biosystems Pty Ltd Sammensætning omfattende VIP eller dets aktive fragmenter til anvendelse ved behandling af aortafibrose
US9029505B2 (en) 2009-08-14 2015-05-12 Phasebio Pharmaceuticals, Inc. Modified vasoactive intestinal peptides
US8916517B2 (en) 2009-11-02 2014-12-23 The Administrators Of The Tulane Educational Fund Analogs of pituitary adenylate cyclase-activating polypeptide (PACAP) and methods for their use
ES2669190T3 (es) 2011-06-06 2018-05-24 Phasebio Pharmaceuticals, Inc. Uso de péptidos intestinales vasoactivos modificados en el tratamiento de la hipertensión
DK3046902T3 (en) * 2013-09-17 2018-12-03 Vectus Biosystems Ltd COMPOSITIONS FOR TREATING HYPERTENSION AND / OR FIBROSE
SG11201601642WA (en) * 2013-09-17 2016-04-28 Vectus Biosystems Ltd Compositions for the treatment of hypertension and/or fibrosis
WO2015172046A1 (en) 2014-05-08 2015-11-12 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating cystic fibrosis
ES2822598T3 (es) 2015-02-09 2021-05-04 Phasebio Pharmaceuticals Inc Métodos y composiciones para tratar enfermedades y trastornos musculares
CN110151973A (zh) * 2019-04-25 2019-08-23 上海交通大学医学院附属瑞金医院 一种生物活性多肽pacap的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3880826A (en) * 1971-09-17 1975-04-29 Sami I Said Vasoactive intestinal peptide
US3862927A (en) * 1973-02-26 1975-01-28 Sami I Said Process for preparation of vasoactive intestinal peptide
WO1988003928A1 (en) * 1986-11-18 1988-06-02 Senetek Plc Method for inducing vaginal lubrication
US4939224A (en) * 1987-02-26 1990-07-03 The Salk Institute Biotechnology/Industrial Associates, Inc. Vasoactive intestinal peptide analogs
US4835252A (en) * 1987-02-26 1989-05-30 The Salk Institute Biotechnology/Industrial Associates, Inc. Vasoactive intestinal peptide analogs
JPH0840926A (ja) * 1994-08-03 1996-02-13 Yakurigaku Chuo Kenkyusho:Kk 皮膚潰瘍治療薬
US6217886B1 (en) * 1997-07-14 2001-04-17 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved micelle compositions
AU2249701A (en) * 1999-11-12 2001-06-06 David Bernstein Methods for treating cardiac arrest or pulmonary hypertension and compositions for use therein comprising vasoactive intestinal polypeptide and cardiac device for electrical and chemical regulation and methods of use
CN1487952A (zh) * 2000-11-28 2004-04-07 �ɶ����＼��ʵ���� 具有血管活性肠肽的生物学活性的用于治疗肺动脉和小动脉高压的化合物
US6911430B2 (en) * 2003-10-01 2005-06-28 Vipogen, Llc Compositions and methods for treating ileus
BRPI0511367B8 (pt) * 2004-06-11 2021-05-25 Vectus Biosystems Ltd uso de uma composição,composição, uso de vip e/ou de um fragmento ativo do mesmo
NZ597677A (en) * 2005-12-09 2013-05-31 Vectus Biosystems Ltd Vip fragments and methods of use

Also Published As

Publication number Publication date
BRPI0511367A (pt) 2007-12-04
RU2007101164A (ru) 2008-07-20
US7951777B2 (en) 2011-05-31
KR101638308B1 (ko) 2016-07-08
CA2573439A1 (en) 2005-12-22
EP1768689A4 (en) 2009-08-12
EP1768689A1 (en) 2007-04-04
ZA200700070B (en) 2008-05-28
AU2005251386A1 (en) 2005-12-22
AU2005251386B8 (en) 2010-10-14
KR20140057411A (ko) 2014-05-12
DK1768689T3 (en) 2014-12-01
ES2523659T3 (es) 2014-11-28
BRPI0511367B1 (pt) 2018-05-22
JP2008501723A (ja) 2008-01-24
HK1102508A1 (en) 2007-11-23
JP4824682B2 (ja) 2011-11-30
KR20160017121A (ko) 2016-02-15
IL179931A0 (en) 2007-05-15
CA2573439C (en) 2014-12-09
US20080108573A1 (en) 2008-05-08
CN1993137A (zh) 2007-07-04
RU2387454C2 (ru) 2010-04-27
WO2005120545A1 (en) 2005-12-22
CN1993137B (zh) 2015-04-22
NZ552130A (en) 2009-10-30
IL179931A (en) 2013-08-29
BRPI0511367B8 (pt) 2021-05-25
AU2005251386B2 (en) 2010-05-13
EP1768689B1 (en) 2014-08-20

Similar Documents

Publication Publication Date Title
MXPA06014462A (es) Composiciones y metodos para tratamiento de enfermedades cardiovasculares.
TW200730538A (en) VIP fragments and methods of use
UA86400C2 (ru) Применение эритропоэтина в низком дозировании для пациентов с дисфункцией эндотелиальных клеток-предшественников, сердечно-сосудистым фактором риска и повреждением конечного органа
MY160560A (en) Compositions and methods for treatment of kidney disorders
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
PT1458360E (pt) Derivados de indole como agonistas do recetor s1p1
SG151327A1 (en) Deazapurines useful as inhibitors of janus kinases
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
WO2007111880A3 (en) Intranasal administration of ketamine to treat depression
MX2007005590A (es) Compuestos del inhibidor glicogeno fosforilasa y sus composiciones farmaceuticas.
EP2335722A3 (en) Use of gelsolin to treat infections
WO2007125545A3 (en) Transmucosal composition
SG146648A1 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
WO2004019884A3 (en) Agents and methods for enhancing bone formation
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
AU2003248888A1 (en) Peptide composition for treatment of sexual dysfunction
MXPA03009772A (es) Metodos y composiciones para tratar lesiones orales y del esofago.
ZA200703166B (en) Composition comprising lactic acid and lactoferrin
WO2007002836A3 (en) Methods and compositions for the prevention and treatment of kidney disease
TW200716172A (en) Pharmaceutical compositions for treating lower motor neuron diseases
EP1482959A4 (en) COMPOSITIONS AND METHODS FOR TREATING SKIN DISORDERS
MXPA04005053A (es) Metodos y composiciones para tratar lesiones del epitelio respiratorio.
WO2004074315A3 (en) Analogues of glp-1
PL1622939T3 (pl) Aktywne warianty białka wiążącego IL-18 i ich medyczne zastosowania

Legal Events

Date Code Title Description
FG Grant or registration